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BACKGROUND and aims: Although the participation of
cytokines in the pathogenesis of rheumatoid arthritis
(RA) seems to be unequivocal, their relationship with
current serum markers of this disease is not clear. The
present study analyses whether there is any correla-
tion between the levels of tumour necrosis factor-a
(TNF-a),  interlukin-2  soluble  receptor  (sIL-2R)  and
the concentrations of C-reactive protein (CRP), eryth-
rocyte sedimentation rate (ESR) and b2-microglobulin
in  a  group  of  21  patients  with  RA, all  rheumatoid
factor positive.
Methods: The levels of TNF-a and sIL-2R were ana-
lysed in association with other parameters of inflam-
mation (ESR, CRP and b2-microglobulin).
Results: In comparison with the control group, RA
patients presented high median levels of both cyto-
kines, TNF-a (6.4pg/ml)  and  sIL-2R (56pmol/L),  as
well  as  of  ESR  (34mm/h),  CRP  (0.9mg/dl)  and
b2-microglobulin  (1.6mg/dl)  (p <  0.01).  However,
only ESR levels in the RA group significantly differ
from the control group (p < 0.01). No correlation was
found between the inflammatory parameters.
Conclusions: These results suggested that TNF-a and
slL-2R levels are up-regulated in RA patients but did
not significantly differ from the control group. Due to
the chronic course of this disease, other inflamma-
tory markers must be identified in order to provide
early therapeutic strategies to these patients.
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Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune
disorder  of  unknown  aetiology1 whose  major  dis-
tinctive feature is a chronic, symmetric, and erosive
synovitis  of  peripheral  joints.  Its  aetiology  is
unknown, and definitive diagnosis depends predom-
inantly  on  characteristic  clinical  features,  typical
radiographic  findings,  the  presence  of  rheumatoid
factor  (RF),  and  elevated erithrocyte sedimentation
rate  (ESR)/C-reactive  protein  (CRP).2,3 Failure  to
meet  these criteria does not  therefore exclude  the
diagnosis,  especially  during  the  early  stages  of  the
disease.  Hence,  diagnosis  is  often  established
months  or  even  years  after  the  first  appearance
of  symptoms,  at  a  stage  where  cartilage  destruc-
tion  has  already  propagated  to  an  irreversible
state.4,5
Although  the  initiating  event  in  RA  has  not  yet
been defined, a growing body of evidence indicates
that  cytokines  may  help  the  development  and  the
perpetuation  of  the  chronic  inflammatory  state.
Among the cytokines involved in RA, tumour necro-
sis  factor-a (TNF-a)  is  believed  to  be  dominant.6,7
This cytokine is present in both the synovial cavity
and the blood of RA patients.7 In  relation to inter-
leukin  (IL)-2,  this  cytokine  is  generally  considered
to  elicit  pro-inflammatory effects  that exacerbate T
helper  cell  type  1-mediated  disease states, such  as
autoimmune arthritis. It has also been demonstrated
that  IL-2  mRNA  is  markedly  increased  during  the
acute  stage  of  collagen-induced  arthritis, an  animal
model of rheumatoid arthritis.8 In this condition, IL-
2 protein and the IL-2 soluble receptor (sIL-2R) are
preferentially expressed at disease onset, in compar-
ison with later stages of the disease.9 However, the
studies that have addressed this theme have shown
discordant  results  since  they  have  reported  evi-
dence  pro  and  against  an  association between  the
current proposed markers of this disease (CRP and
ESR)  and  cytokines  (TNF-a and  sIL-2R).  In  the
present  study,  we  examined  this  issue  again  by
evaluating whether there is any correlation between
cytokine  (TNF-a and  sIL-2R)  levels  and  inflamma-
tory  parameters  such  as  ESR,  CRP,  and  b2-micro-
globulin concentrations.
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Subjects
The  patients with  RA  were  enrolled  from  the  out-
patient  clinical  service  of  the  University  Hospital-
UFSC  by  reviewing  their  medical  records.  Only
patients with positive results for RF who fulfilled the
American College of Rheumatology diagnostic criteria
for RA10,11 were selected for inclusion in the study.
Exclusion criteria were the presence of other acute or
chronic  inflammatory  diseases.  Apparently  healthy
persons were asked to participate as controls if they
had negative RF values and an absence of acute and
chronic  diseases.  All  patients  and  subjects  gave
informed consent, and the Medical Ethics Committee
of  the  Universidade  Federal  of  Santa  Catarina
approved the study protocol.
Procedures
All laboratory specimens for the study were collected
at the time the patients came to the clinical laboratory
for other reasons. Blood samples were drawn from
the  antecubital  vein  in  the  fasting  state.  Some
evaluations  such  as  ESR,  RF  and  haematological
parameters were made as part of a standard battery of
assessments requested by their doctors. Samples were
collected in different tubes according to the type of
analysis. ESR and haematological parameters (red and
white blood cell indices: number, haematocrit, hae-
moglobin, platelet number) were obtained from the
samples  using  different  anticoagulant  solutions:
sodium  citrate  and  ethylenediaminetetracetic  acid,
respectively.  Silicone-coated  tubes  were  used  for
other analyses [cytokines, CRP, RF, immunoglobulins
G andM (IgG and IgM), complement components (C3
and C4), b2-microglobulin and anti-nuclear antibody
(ANA) assays]. After being centrifuged, coded serum
aliquots  were  stored  at  –20°C  and  analysed  for
cytokines, CRP, RF, IgG, IgM, C3, C4, b2-microglobulin
and ANA in a single batch at the end of the study. The




On  the  day  of  the  measurements  of  the  studied
parameters,  the  samples  were  thawed  to  room
temperature. Both  TNF-aand sIL-2R were measured by
enzyme-linked  immunosorbent  assay  (Boehringer
Mannheim Biochemical, Indianapolis, Indiana, USA)
methodologies. The ranges of the values detected by
these assays were: TNF-a, 5–1000pg/ml; and sIL-2R,
50–100pmol/l. The principle of these tests is based on
the  two-step  sandwich  techniques.  Briefly,  sample
aliquots and standards (20ml) were transferred to the
wells of a microtitre plate (TNF-a, 5–1000pg/ml; sIL-
2R, 5–100pmol/l) and incubated at room temperature
(4h). Then the samples were washed three times with
washing solution (composition: NaCl, 137 mM; KCl,
2 mM; and phosphate, 10 mM; pH 7.6), followed by
the addition of 200ml of substrate solution into the
wells. The microtitre plate was then protected from
light  and  maintained  at  room  temperature
(20–30min). The  reaction  was  stopped  by  adding
50ml of sulphuric acid (1mol/l). One minute later, the
concentration of cytokines in  each well  was deter-
mined  (Organon Teknika,  Durham,  North  Carolina,
USA).  When  indicated  by  the  manufacturer,  the
procedures were carried out on a shaker (250r.p.m.).
CRP, RF, IgG and IgM, complement components
(C3, C4) and ANA assays
CRP (cut-off, 0.8mg/dl), RF (cut-off, < 20IU/ml), IgG
(reference  range,  694–1618mg/dl),  IgM  (reference
range,  60–263mg/dl),  C3  (reference  range,
88–210mg/dl) and C4 (reference range, 16–47mg/
dl) were measured by nephelometry (Beckman Coul-
ter  Array,  Brea,  California,  USA),  b2-microglobulin
(1.01–1.73mg/dl)  was  determined  by  the  chem-
iluminescence method (Immulite 2000; DPC Medlab,
Dade, Boehringer, Deerfield, Illinois, USA) and leuko-
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Table 1. Clinical and laboratorial features of the studied groups
Parameter RA Control
Sex (female:male) 18:3  7:0 
Age (years) 36 (16–75)* 29 (20–75)
Haemoglobin (g/dl) 13.6 (10.1–15.1) 13.2 (11.7–14.5)
Haematocrit (%) 40.4 (29.7–46.3) 39.5 (36.7–45.1)
Platelet number (´ 10
3mm
3) 237 (148–795) 290 (205–344)
Granulocytes (´ 10
3 mm
3) 4.7 (2.79–16.7) 4.2 (2.2–6.4)
White blood cell (´ 10
3 mm
3) 6.3 (6.1–18.8) 6.9 (5.4–10.2)
IgG (mg/dl) 847 (549–1145) 160 (70.5–902.3)
IgM (mg/dl) 93.8 (36.7–749) 70.2 (56.9–86.1)
C3 (mg/dl) 108 (54–311) 88 (88–158)
C4 (mg/dl) 23 (10–75.4) 16.9 (10–83)
*Data presented as median (range) apart from the female:male ratio.cyte  indexes  were  determined  on  an  automatic
counting machine (Beckman-Coulter). The ESR (cut-
off values: female, < 20mm/h; male, < 15mm/h) was
measured by the Westergreen method (automatic Ves-
mastic-20,  Miami,  Florida,  USA).  ANA  tests  were
evaluated  by  indirect  immunofluorescence  assays
using human epithelial cell (HEP-2) slides.10
Statistical analysis
When indicated, the Mann-Whitney test, single linear
regression test or correlation (Pearson) analysis were
used. For all  analyses, p < 0.05  was used to assess
overall differences. The results are expressed as the
median and its range.
Results
The present study included a series of 21 patients; all
fulfilled the American College of Rheumatology Diag-
nostic  Criteria  for  RA,10,11 and  seven  apparently
healthy individuals were used as controls. The gender
ratio was 18 females to three males for RA patients
and seven females to zero males for the control group.
All patients were white. The median age of the groups
was 36 years (range 16–75 years) for the RA group
and  29  years  (range  20–75  years)  for  the  control
group.
Table 1 presents some of the features of the studied
groups. As shown, no evidence of anaemia or changes
in either platelet or white cell numbers, levels of IgG
and IgM  or complement factors (C3 and C4) were
detected  in  RA  patients  (Table  1)  (p >  0.05).  In
comparison  with  the  control  group,  RA  patients
presented increased levels of ESR, CRP, and b2-micro-
globulin (p < 0.01) (Fig. 1A-C). The median levels of
ESR  in  RA  and  groups  were  34mm/h  (range
3.0–88mm/h), whereas those for CRP and b2-micro-
globulin  concentrations  were  0.9mg/dl  (range
0.08–58mg/dl) and 1.6mg/dl (range 0.84–2.0mg/dl),
respectively. In this studied group of RA patients, only
ESR levels significantly differ from control group (p <
0.01).  Both  TNF-a (median  6.4pg/ml,  range
2.8–450pg/ml) and sIL-2R (median 56pmol/l, range
12.5–341pmol/l) levels were also enhanced in the RA
patients  (Fig.  2A,B)  but  they  did  not  differ  in
comparison with control data.
Table  2  shows  that  a  significant  correlation  was
only  found  between TNF-a and  sIL-2R  (p <  0.01).
However, this statistical significance may be artifac-
tual since no statistical significance was found for the
TNF-a and sIL-2R levels in rheumatoid arthritis
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FIG. 1. Individual values of ESR (A), CRP (B) and b2-micro-
globulin (C) in both control and RA groups. The dotted line
indicates the median.
FIG. 2. Individual values of TNF-a (A) and sIL-2R (B) in both
control  and  RA  groups.  The  dotted  line  indicates  the
median.data of a patient that presented the highest levels of
both cytokines from the RA group.
Discussion
The results presented show that the median levels of
TNF-a, sIL-2R and CRP, although slightly increased in
RA patients, did not differ from a group of apparently
healthy subjects. In the RA group, these findings were
associated with high levels of ESR, whereas b2-micro-
globulin  concentrations also did not differ.  Overall,
these  changes  are  representative  of  a  spectrum  of
effects that are triggered in response to the autoim-
mune injury that characterizes RA.
Several clinical and experimental lines of evidence
point to TNF-a as an important inflammatory media-
tor in  RA.6,7 It  is well  known that this cytokine is
found  at  high  levels  in  the  synovial  fluids  of  RA
patients,  and  that it  contributes  to  both  bone  and
cartilage  destruction.12 On  the  other  hand,  experi-
mental models of arthritis in mice have demonstrated
that TNF-a injection  accelerates  arthritis,  whereas
anti-TNF-a injection  prevents  it.6 In  our  work,  we
observed that the median blood levels of this cytokine
did not significantly differ in comparison with those
measured in the control group. Considering that the
studied RA patients were also RF-positive, an indicator
of  disease  severity,  the  relevance of  these  findings
remains to be established.13,14
Few  studies  in  the  literature  have  evaluated  the
levels of sIL-2R in RA patients. Suenaga et al.15 have
demonstrated that an increased concentration of sIL-
2R  in  the  serum  of  patients  with  joint  pain  is  a
predictor for the future development of RA. Spadaro
et al.16 observed that treatment of RA patients with
methotrexate for 6 months was able to decrease the
levels of both sIL-2R and IL-6. On the other hand, the
levels of sIL-2R did not correlate with any future bone
or joint changes within 1 year of observation.17 In the
present study, the serum concentrations of sIL-2R did
not significantly  differ in comparison with those of
controls,  whereas  ESR  levels  but  not  CRP  and
b2-microglobulin  were  significantly  increased  Alto-
gether, these inflammatory indices seem to independ-
ently reflect a final pathway of multifactorial events.
Another point that deserves consideration is the fact
that, despite adequate control of  symptoms  in  this
disease,  the  available  therapeutic  measures  do  not
prevent further progression of this disease that results
in high levels of disability.18,19Advances in this field are
urged and the provision of adequate therapy is now a
common  goal  for  several  chronic  diseases.  In  this
regard,  ultra-sensitive  assays  of  polymerase  chain
reaction have been used both as markers and prog-
nostic predictors of cardiovascular disease.20,21 How-
ever, treatment evaluation was not addressed in our
work and the small number of RA patients did not
permit further conclusions in relation to the polymer-
ase chain reaction levels that were measured by ultra-
sensitive assay.
In conclusion, the present results show that, in this
group  of RA patients, all  RF  negative, the  elevated
levels  of  ESR  did  not  correlate  with  the  studied
cytokine  levels. According  to  these  findings,  other
inflammatory markers must be searched in order to
provide early therapeutic strategies to these group of
patients.
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